CA-AERA-TECHNOLOGY
24.9.2020 14:02:16 CEST | Business Wire | Press release
Aera Technology today announced the general availability of the Aera Cognitive Operating System™, the world's first cloud platform for Cognitive Automation . In extending availability beyond current customers and partners, including Merck, RB, and Unilever, Aera meets the growing need of companies whose operations have been impacted by changing or uncertain market conditions.
“We’ve worked with the world's largest organizations and complex supply chains to demonstrate the value of Cognitive Automation at scale. This tight collaboration has enabled us to build the Aera Cognitive Operating System™, which is now easy to implement and scale, and therefore available to an even wider range of companies,” said Frederic Laluyaux, CEO of Aera Technology.
Alessandro de Luca, CIO of Healthcare, Merck Group, noted, “We are all running on much shorter cycles in this dynamic world, and it is impossible to process everything manually or on legacy systems. Aera's Cognitive Operating System™ has made a real difference in our ability to implement and operate a best-in-Class IBP process. This, combined with the fact that we could rely on a single, intelligent source of truth, gave us a springboard to agility.”
“Cognitive Automation plays a large role in the 4th industrial revolution,” said Nokuthula Lukhele, Project Lead, Data, and Digital Transformation, World Economic Forum. “The future of agility needs to be at the edge of decision making, and these technologies enable that,” she added.
The Aera Cognitive Operating System™ augments and enhances human decisions, providing a centralized corporate brain - adding agility to enterprise systems. By applying data crawling, machine learning, and industry models, Aera’s system makes real-time recommendations, predicts outcomes, and acts autonomously to aid complex decisions - from inventory optimization and touchless planning to order management and trade promotions.
“There is a limit of what the human mind can do with the volume of data and analytics needed to optimize a supply chain,” said Bish Sen, Head of Supply Chain Beauty & Personal Care, Transformation, Planning & Engineering at Unilever. “This is where agility is more important than accuracy, and Cognitive Automation can help unlock those levels of agility.”
“Designing and managing a supply chain that balances customer service, cost, and resiliency requires a model that constantly measures and reacts to value at risk. Kearney’s Sense & Pivot approach, combined with Aera’s Cognitive Operating System™, provides a proven solution agile enough to respond to this challenge by delivering real-time Cognitive Automation at scale for corporate boards and supply chain leaders.” - Suketu Gandhi, Partner, Global Leader - Digital Supply Chain, Kearney.
Aera Technology is hosting the Cognitive Automation Summit on September 24, 2020. This first summit dedicated to Cognitive Automation offers a unique opportunity to understand how the tectonic shift in cloud-scale and in artificial intelligence, along with radical market volatility are forcing enterprises to redefine agility. Thought leaders and pioneers from world-leading organizations will share how they leverage Aera’s Cognitive Operating System™ to achieve previously unattainable levels of financial and operational performance - without trade-offs.
For more information, visit https://cognitiveautomationsummit.com/ .
Aera also announced this week the launch of Aera Developer™, a self-service integrated development environment, which has been purpose-built for implementing Cognitive Automation at scale. It integrates each component of Data, Science, Process, and Change, so that it has all of the capabilities necessary for building Cognitive Skills, all rolled into one seamless user experience.
About Aera Technology
Aera Technology delivers the Cognitive Operating System™ that enables the Self-Driving Enterprise™. Aera understands how businesses work; makes real-time recommendations; predicts outcomes; and acts autonomously. Using proprietary data crawling, industry models, machine learning and artificial intelligence, Aera is revolutionizing how people relate to data and how organizations function. Headquartered in Mountain View, California, Aera services some of the world's largest enterprises from its global offices located in San Francisco, Bucharest, Cluj-Napoca, Paris, Munich, London, Pune, and Sydney. For more information about Aera, please visit www.aeratechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom